<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Psoriatic juvenile idiopathic arthritis: Management and prognosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Psoriatic juvenile idiopathic arthritis: Management and prognosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Psoriatic juvenile idiopathic arthritis: Management and prognosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter A Nigrovic, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marisa Klein-Gitelman, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth TePas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 29, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H22628149">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Psoriatic juvenile idiopathic arthritis (psJIA), or alternately juvenile psoriatic arthritis (JPsA), is a condition that can range widely in presentation and severity. Frank cutaneous psoriasis is not always evident, and the extent of articular involvement may vary from mild enthesitis (inflammation of sites at which ligaments, tendons, and other fibrous structures insert into bone) to polyarticular involvement of multiple axial (spine, sacroiliac joints) and peripheral joints.
        </p>
        <p>
         The treatment and prognosis of psJIA are discussed here. The epidemiology, pathogenesis, clinical manifestations, and diagnosis of psJIA are discussed separately, as is psoriatic arthritis in adults. (See
         <a class="medical medical_review" href="/z/d/html/16630.html" rel="external">
          "Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7784.html" rel="external">
          "Clinical manifestations and diagnosis of psoriatic arthritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7793.html" rel="external">
          "Treatment of psoriatic arthritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7791.html" rel="external">
          "Pathogenesis of psoriatic arthritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7137357">
         <span class="h1">
          MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory tests and imaging studies are of limited value in the management of psJIA. As in other subtypes of JIA, destructive arthritis may continue in the face of normal laboratory studies. Similarly, as with JIA generally, the role of conventional radiography in the day-to-day management of arthritis also is small since bony changes take months or years to become evident. Treatment should not be withheld because radiologic changes are not yet evident. Rather, careful clinical monitoring of the physical exam remains of paramount importance in following children with psoriatic arthritis. Monitoring for uveitis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16630.html" rel="external">
          "Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Laboratory findings'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16630.html" rel="external">
          "Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Radiologic studies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6415.html" rel="external">
          "Oligoarticular juvenile idiopathic arthritis", section on 'Uveitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22628165">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment recommendations for psJIA are derived from trials in other JIA subtypes and from adult psoriatic arthritis since few randomized controlled trials (RCTs) have been conducted specifically in psJIA [
         <a href="#rid1">
          1
         </a>
         ]. Management should be conducted in consultation with a pediatric rheumatologist and pediatric ophthalmologist whenever possible.
        </p>
        <p class="headingAnchor" id="H22628173">
         <span class="h2">
          Peripheral arthritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment priority in psJIA, as in other types of JIA, is to extinguish synovitis in order to avoid damage to cartilage and bone. This imperative is particularly critical for the growing skeleton, where injury to growth plates and growth centers can cause permanent derangement of bone shape and length [
         <a href="#rid2">
          2,3
         </a>
         ]. Absence of reported pain and lack of functional impairment are imperfect guides to successful therapy since children may adapt remarkably well to ongoing arthritis [
         <a href="#rid4">
          4
         </a>
         ]. Such children may still go on to experience substantial joint injury, developing functional impairment later in childhood or as young adults [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         The basic treatment algorithm of psJIA is similar to that employed in other subtypes of JIA  (
         <a class="graphic graphic_table graphicRef64063" href="/z/d/graphic/64063.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. More than 80 percent of psJIA patients are treated with
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          methotrexate
         </a>
         , and more than half receive tumor necrosis factor (TNF) antagonists over the course of their illness [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonsteroidal antiinflammatory drugs (NSAIDs) are employed initially as the sole therapy by some rheumatologists but typically do not induce remission and are
         <strong>
          inappropriate
         </strong>
         as monotherapy for synovitis that persists beyond two months of treatment [
         <a href="#rid1">
          1
         </a>
         ]. Initiation of
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          methotrexate
         </a>
         at diagnosis is preferable to delaying therapy while awaiting the result of an NSAID trial in patients presenting with moderate or severe arthritis, erosive disease, or arthritis of multiple joints [
         <a href="#rid1">
          1
         </a>
         ]. NSAIDs are used to help control swelling and pain while awaiting the onset of antirheumatic activity of disease-modifying antirheumatic drugs (DMARDs).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individual large joints can be treated effectively with intraarticular (IA) glucocorticoid injection. psJIA has not been specifically studied, but decision analysis in oligoarticular JIA suggests that a strategy of upfront IA glucocorticoid injection is preferable to a trial of NSAIDs followed by IA for refractory disease due to the low probability (approximately 16 percent) that NSAIDs will induce remission within two months [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dactylitis in psoriatic arthritis reflects a composite of arthritis of the finger or toe joints, tenosynovitis, and, in particular, enthesitis of the many attachments of ligaments, tendons, and joint capsules in the digit [
         <a href="#rid8">
          8
         </a>
         ]. Scintigraphic studies confirm the presence of TNF localized to the dactylitic digit [
         <a href="#rid9">
          9
         </a>
         ]. Psoriatic dactylitis can be treated effectively with glucocorticoid injection into the digital flexor tendon sheath, with a response rate of 87 percent in one adult observational series [
         <a href="#rid10">
          10
         </a>
         ]. Traditional DMARDs such as
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          methotrexate
         </a>
         generally appear to have limited utility, although improvement of dactylitis with treatment has been reported [
         <a href="#rid11">
          11
         </a>
         ]. By contrast, dactylitis in adult psoriatic arthritis responds well to therapy with TNF inhibitors, interleukin (IL) 12/23 blockade (
         <a class="drug drug_pediatric" data-topicid="126474" href="/z/d/drug information/126474.html" rel="external">
          ustekinumab
         </a>
         ), IL-17 blockade, phosphodiesterase-4 (PDE4) inhibition (
         <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">
          apremilast
         </a>
         ), and Janus kinase (JAK) inhibitors [
         <a href="#rid12">
          12-16
         </a>
         ]. In children, TNF inhibitors are typically the first biologic selected for this purpose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         DMARDs are indicated at diagnosis in patients with involvement of multiple joints [
         <a href="#rid1">
          1
         </a>
         ]. The most commonly used DMARD is
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          methotrexate
         </a>
         . Methotrexate is associated with a higher risk of hepatotoxicity in adults with psoriatic arthritis than in those with rheumatoid arthritis, possibly because of the higher prevalence of obesity and associated steatohepatitis in adult psoriasis, but methotrexate is typically well tolerated in children with psJIA [
         <a href="#rid17">
          17
         </a>
         ].
         <a class="drug drug_pediatric" data-topicid="12817" href="/z/d/drug information/12817.html" rel="external">
          Sulfasalazine
         </a>
         is an alternative, especially for lower-extremity large-joint arthritis, although trial data in adult psoriatic arthritis provide conflicting evidence of efficacy [
         <a href="#rid18">
          18-21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Failure to achieve remission is addressed by substitution or addition of a second oral DMARD, such as
         <a class="drug drug_pediatric" data-topicid="131651" href="/z/d/drug information/131651.html" rel="external">
          leflunomide
         </a>
         , or more commonly by institution of anti-TNF therapy with any of the available agents [
         <a href="#rid1">
          1
         </a>
         ]. TNF blockade is particularly useful when there is axial disease since conventional DMARDs are not effective for inflammation of the spine and sacroiliac joints. Anti-TNF agents are also effective for dactylitis and enthesitis [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7966.html" rel="external">
          "Overview of biologic agents in the rheumatic diseases", section on 'TNF inhibition'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="132381" href="/z/d/drug information/132381.html" rel="external">
          Secukinumab
         </a>
         (a human IL-17A antagonist) exhibits efficacy in adult psoriatic arthritis comparable with TNF inhibition and is superior in improvement of associated skin psoriasis, with comparable safety [
         <a href="#rid22">
          22
         </a>
         ]. Secukinumab is also effective with respect to axial arthritis [
         <a href="#rid23">
          23
         </a>
         ]. A randomized withdrawal trial of secukinumab in children with psJIA and enthesitis related arthritis (ERA) showed efficacy, with safety generally comparable with that reported in adult disease [
         <a href="#rid24">
          24
         </a>
         ]. Secukinumab is approved for psJIA in children ≥2 years of age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical similarities between adult and pediatric psoriatic arthritis suggest that they form a spectrum of disease, a possibility supported by genetic evidence [
         <a href="#rid25">
          25-27
         </a>
         ]. Based upon this similarity, agents useful in adult psoriatic arthritis are likely to be effective in psJIA efficacy, including
         <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">
          apremilast
         </a>
         (a PDE4 inhibitor) and
         <a class="drug drug_pediatric" data-topicid="12731" href="/z/d/drug information/12731.html" rel="external">
          abatacept
         </a>
         (a T cell costimulatory blocker), the latter only modestly effective for psoriatic arthritis but effective and well tolerated in polyarticular-course JIA [
         <a href="#rid28">
          28-30
         </a>
         ]. The IL-12/23 inhibitor
         <a class="drug drug_pediatric" data-topicid="126474" href="/z/d/drug information/126474.html" rel="external">
          ustekinumab
         </a>
         has efficacy in adult psoriatic arthritis and, based upon extrapolation from studies in pediatric psoriasis and in adult psoriatic arthritis, is approved for use in pediatric psoriasis and psoriatic arthritis for patients age six years and older [
         <a href="#rid31">
          31-33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7793.html" rel="external">
          "Treatment of psoriatic arthritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some rheumatologists believe that psoriatic arthritis is less responsive to systemic glucocorticoids than other types of arthritis, but this observation has yet to be rigorously tested. Systemic glucocorticoids can provoke a flare of cutaneous psoriasis when tapered [
         <a href="#rid34">
          34
         </a>
         ]. Some data also suggest a risk for worsening psoriasis with antimalarials such as
         <a class="drug drug_pediatric" data-topicid="13366" href="/z/d/drug information/13366.html" rel="external">
          hydroxychloroquine
         </a>
         [
         <a href="#rid35">
          35
         </a>
         ]. These agents are therefore avoided when possible, although low-to-moderate-dose systemic glucocorticoids are sometimes employed as short-term "bridge" therapy while awaiting the effect of slower-acting DMARDs in highly symptomatic patients.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22628181">
         <span class="h2">
          Spondylitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of psoriatic spondylitis in children is based primarily upon experience with ankylosing spondylitis (AS) [
         <a href="#rid36">
          36-38
         </a>
         ]. Based upon observational data, our practice is to initiate anti-TNF therapy in all children with confirmed sacroiliitis, employing NSAIDs as adjuvant therapy if needed to provide complete symptomatic relief. (See
         <a class="medical medical_review" href="/z/d/html/6421.html" rel="external">
          "Spondyloarthritis in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7790.html" rel="external">
          "Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults"
         </a>
         .)
        </p>
        <p>
         Axial disease in psJIA tends to run a milder course than in AS [
         <a href="#rid39">
          39
         </a>
         ]. Treatment should be initiated in patients with psJIA who experience axial symptoms or show limitation of spinal mobility, even if changes have not yet developed on plain radiograph [
         <a href="#rid36">
          36
         </a>
         ]. Of note, spinal radiographs are much less sensitive in detecting early sacroiliitis than magnetic resonance imaging (MRI), and, therefore, we typically avoid plain radiographs and instead employ noncontrast MRI as the preferred mode of imaging in children with symptoms suggestive of sacroiliitis [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         The benefit of continuous NSAID therapy is uncertain. In one adult trial, standing-dose versus as-needed NSAIDs resulted in measurable radiographic improvement, but the effect was small, and the finding was not replicated in a second comparably sized RCT [
         <a href="#rid41">
          41,42
         </a>
         ]. In one observational study, standing-dose NSAIDs were associated with a 12 percent increase in incident hypertension [
         <a href="#rid43">
          43
         </a>
         ]. There are no data that evaluate the role of NSAIDs in the setting of anti-TNF therapy. Standard DMARDs, including
         <a class="drug drug_pediatric" data-topicid="12817" href="/z/d/drug information/12817.html" rel="external">
          sulfasalazine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          methotrexate
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="131651" href="/z/d/drug information/131651.html" rel="external">
          leflunomide
         </a>
         , are of minimal benefit. Anti-TNF therapy is highly effective for axial disease in JIA [
         <a href="#rid44">
          44
         </a>
         ]. Studies in adults with longstanding disease have not shown reduced radiographic progression, although data do support the possibility that early initiation of therapy may result in a more favorable outcome [
         <a href="#rid45">
          45-49
         </a>
         ]. Early initiation may be particularly important in young people because early-onset spondyloarthropathies may run a more destructive course than later-onset disease [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         Evidence from adult patients confirms that therapy directed against IL-17 can benefit axial disease, including patients whose disease has not responded to TNF inhibitors [
         <a href="#rid51">
          51-55
         </a>
         ].
         <a class="drug drug_pediatric" data-topicid="132381" href="/z/d/drug information/132381.html" rel="external">
          Secukinumab
         </a>
         (anti-IL-17A) has been tested in psJIA and in the pediatric equivalent of AS, ERA, and is approved for used in psJIA in children ≥2 years of age [
         <a href="#rid24">
          24
         </a>
         ]. JAK inhibitors such as
         <a class="drug drug_pediatric" data-topicid="134956" href="/z/d/drug information/134956.html" rel="external">
          upadacitinib
         </a>
         have clinical efficacy in adults with active AS [
         <a href="#rid56">
          56
         </a>
         ].
         <a class="drug drug_pediatric" data-topicid="126474" href="/z/d/drug information/126474.html" rel="external">
          Ustekinumab
         </a>
         is not typically effective for axial disease [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H22628189">
         <span class="h2">
          Uveitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment for uveitis in psJIA is similar to that in other subtypes of JIA. Chronic anterior uveitis is treated initially with topical corticosteroids, usually together with oral or subcutaneous
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          methotrexate
         </a>
         . Resistant disease often responds to an anti-TNF antibody such as
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">
          adalimumab
         </a>
         (the anti-TNF receptor fusion protein
         <a class="drug drug_pediatric" data-topicid="13284" href="/z/d/drug information/13284.html" rel="external">
          etanercept
         </a>
         is less effective for uveitis). Third-line agents include
         <a class="drug drug_pediatric" data-topicid="12624" href="/z/d/drug information/12624.html" rel="external">
          mycophenolate
         </a>
         mofetil and
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         . Acute anterior uveitis may also occur, typically in children with axial disease; this form of uveitis is less frequently sight threatening than chronic anterior uveitis and typically responds to topical corticosteroids or oral glucocorticoids. These options are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5592.html" rel="external">
          "Uveitis: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6415.html" rel="external">
          "Oligoarticular juvenile idiopathic arthritis", section on 'Uveitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22628197">
         <span class="h2">
          Cutaneous disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cutaneous manifestations of pediatric psoriasis are phenotypically similar to skin involvement in adults regardless of whether there is concomitant arthritis. The only exception is a higher prevalence of nail changes in psJIA [
         <a href="#rid58">
          58
         </a>
         ]. Conventional psoriasis treatment is appropriate for skin disease associated with psJIA, although articular manifestations favor use of systemic agents that are also effective for skin disease, including
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          methotrexate
         </a>
         , TNF blockers,
         <a class="drug drug_pediatric" data-topicid="126474" href="/z/d/drug information/126474.html" rel="external">
          ustekinumab
         </a>
         , and the IL-17 antagonist
         <a class="drug drug_pediatric" data-topicid="132381" href="/z/d/drug information/132381.html" rel="external">
          secukinumab
         </a>
         . Data from adult psoriasis and psoriatic arthritis suggest that therapy directed against IL-17 is likely to provide the best relief for resistant cutaneous psoriasis. (See
         <a class="medical medical_review" href="/z/d/html/16630.html" rel="external">
          "Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Skin and nail disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">
          "Treatment of psoriasis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7793.html" rel="external">
          "Treatment of psoriatic arthritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H359172558">
         <span class="h1">
          IMMUNIZATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The administration of live-virus vaccines and other standard childhood immunizations in patients with JIA is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6415.html" rel="external">
          "Oligoarticular juvenile idiopathic arthritis", section on 'Immunizations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22628205">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The long-term outcome of children with psJIA has improved with the expanding repertoire of agents available. Clinical remission (on medication) is achieved in the majority of patients in both older and younger subgroups [
         <a href="#rid59">
          59,60
         </a>
         ]. Nevertheless, compared with other patients with JIA, observational data suggest that those with psoriatic arthritis accumulate more inflamed joints and are less likely to enter sustained remission [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
         Among patients with psJIA followed for at least five years, from the prebiologic era (before approximately 2000 in pediatric rheumatology), persistently active disease was found in 70 percent and physical activity limitations in one-third [
         <a href="#rid62">
          62
         </a>
         ]. In another series of children with JIA first admitted between 1980 and 1985 and followed for at least 15 years, 33 percent of patients with psJIA still required disease-modifying antirheumatic drug (DMARD) therapy [
         <a href="#rid63">
          63
         </a>
         ]. Poor outcomes and long-term disability were seen principally in patients who experienced a long delay in diagnosis or in whom effective therapy was not instituted, often through clinician or caregiver reluctance to take the steps necessary to induce remission. In contrast, 91 percent of patients with psJIA in a large cohort of children diagnosed with JIA from 2005 to 2010 attained inactive disease within two years, and 47 percent achieved remission (defined as inactive disease &gt;12 months after discontinuing treatment) within five years [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3973151810">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112604.html" rel="external">
          "Society guideline links: Juvenile idiopathic arthritis"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/118570.html" rel="external">
          "Society guideline links: Uveitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H531054889">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/86740.html" rel="external">
          "Patient education: Psoriatic arthritis in children (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22628213">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psoriatic juvenile idiopathic arthritis (psJIA), or alternately juvenile psoriatic arthritis (JPsA), is a relatively common subtype of JIA, but its clinical presentation can be highly variable. (See
         <a class="medical medical_review" href="/z/d/html/16630.html" rel="external">
          "Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6412.html" rel="external">
          "Classification of juvenile idiopathic arthritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Laboratory tests and radiologic studies are of limited value in the management of psJIA, aside from the confirmation of suspected sacroiliitis with noncontrast magnetic resonance imaging (MRI). (See
         <a class="local">
          'Monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The treatment priority in psJIA, as in other types of JIA, is to extinguish all clinical, laboratory, and radiographic manifestations of synovitis in order to avoid damage to cartilage and bone. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The basic treatment algorithm of psJIA is similar to that employed in other subtypes of JIA, with a few exceptions  (
         <a class="graphic graphic_table graphicRef64063" href="/z/d/graphic/64063.html" rel="external">
          table 1
         </a>
         ). Nonsteroidal antiinflammatory drugs (NSAIDs) are used as initial monotherapy by some rheumatologists. However, NSAIDs typically do not induce remission and, therefore, are generally better used as adjuncts to DMARDs in patients with widespread or moderate-to-severe disease. Arthritis in individual large joints, as well as dactylitic digits, may be treated with glucocorticoid injections. Disease-modifying antirheumatic drugs (DMARDs) are indicated at diagnosis in patients with involvement of multiple joints and in those whose disease does not go into remission with intraarticular (IA) glucocorticoids. Continued disease activity is addressed by addition of a second DMARD or, more commonly, by institution of anti-tumor necrosis factor (TNF) therapy. Patients with disease resistant to TNF inhibitors are treated with
         <a class="drug drug_pediatric" data-topicid="132381" href="/z/d/drug information/132381.html" rel="external">
          secukinumab
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="126474" href="/z/d/drug information/126474.html" rel="external">
          ustekinumab
         </a>
         , agents that can be especially helpful in the setting of resistant cutaneous psoriasis. Systemic glucocorticoids are employed less commonly, and antimalarial agents are generally avoided due to a risk of worsening the psoriatic rash. (See
         <a class="local">
          'Peripheral arthritis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Axial disease in psJIA is phenotypically similar to ankylosing spondylitis (AS). Treatment should be initiated in patients with psJIA who experience axial symptoms or show limitation of spinal mobility, even if changes have not yet developed on plain radiograph. Anti-TNF agents are generally the most effective, while NSAIDs can provide relief to some patients. Blockade of interleukin (IL) 17 as well as Janus kinase (JAK) inhibition (though not IL-12/23 blockade) have documented efficacy for axial disease in adults and are increasingly used in children, although given the extensive track record with TNF inhibitors, we reserve these newer agents for refractory disease. (See
         <a class="local">
          'Spondylitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monitoring for and treatment of uveitis in psJIA are similar to that in other subtypes of JIA. (See
         <a class="local">
          'Uveitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Conventional psoriasis treatment is appropriate for skin disease associated with psJIA. Frequently, this is not an issue, since articular manifestations may drive early use of systemic agents that are highly effective for skin disease, including
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          methotrexate
         </a>
         and TNF blockers. (See
         <a class="local">
          'Cutaneous disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poor outcomes and long-term disability are seen principally in patients who had a long delay in diagnosis and/or in whom effective therapy was not instituted, often through clinician or caregiver reluctance to take the steps necessary to induce remission. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Rheumatol 2019; 71:846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon S, Whiffen J, Shapiro F. Leg-length discrepancies in monoarticular and pauciarticular juvenile rheumatoid arthritis. J Bone Joint Surg Am 1981; 63:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ANSELL BM, BYWATERS EG. Growth in Still's disease. Ann Rheum Dis 1956; 15:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGhee JL, Burks FN, Sheckels JL, Jarvis JN. Identifying children with chronic arthritis based on chief complaints: absence of predictive value for musculoskeletal pain as an indicator of rheumatic disease in children. Pediatrics 2002; 110:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nigrovic PA, White PH. Care of the adult with juvenile rheumatoid arthritis. Arthritis Rheum 2006; 55:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beukelman T, Ringold S, Davis TE, et al. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol 2012; 39:1867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beukelman T, Guevara JP, Albert DA. Optimal treatment of knee monarthritis in juvenile idiopathic arthritis: a decision analysis. Arthritis Rheum 2008; 59:1580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuttle KS, Vargas SO, Callahan MJ, et al. Enthesitis as a component of dactylitis in psoriatic juvenile idiopathic arthritis: histology of an established clinical entity. Pediatr Rheumatol Online J 2015; 13:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carron P, Lambert B, Van Praet L, et al. Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis. RMD Open 2016; 2:e000265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girolimetto N, Macchioni P, Citriniti G, et al. Effectiveness of steroid injection for hand psoriatic dactylitis: results from a multicentre prospective observational study. Clin Rheumatol 2020; 39:3383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coates LC, Helliwell PS. Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study. J Rheumatol 2016; 43:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014; 73:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kavanaugh A, Puig L, Gottlieb AB, et al. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann Rheum Dis 2016; 75:1984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis 2018; 77:890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology (Oxford) 2018; 57:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mease P, Hall S, FitzGerald O, et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med 2017; 377:1537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006; 33:1422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998; 41:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brooks CD. Sulfasalazine for the management of juvenile rheumatoid arthritis. J Rheumatol 2001; 28:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta AK, Grober JS, Hamilton TA, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995; 22:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Combe B, Goupille P, Kuntz JL, et al. Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J Rheumatol 1996; 35:664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet 2020; 395:1496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis 2021; 80:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunner HI, Foeldvari I, Alexeeva E, et al. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann Rheum Dis 2023; 82:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hinks A, Bowes J, Cobb J, et al. Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases. Ann Rheum Dis 2017; 76:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zisman D, Gladman DD, Stoll ML, et al. The Juvenile Psoriatic Arthritis Cohort in the CARRA Registry: Clinical Characteristics, Classification, and Outcomes. J Rheumatol 2017; 44:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nigrovic PA, Colbert RA, Holers VM, et al. Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev Rheumatol 2021; 17:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011; 63:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mease PJ, Gottlieb AB, van der Heijde D, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis 2017; 76:1550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McInnes IB, Chakravarty SD, Apaolaza I, et al. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2. RMD Open 2019; 5:e000990.
          </a>
         </li>
         <li class="breakAll">
          Stelara (ustekinumab) approved by the US Food and Drug Administration to treat pediatric patients with acive psoriatic arthritis. Johnson &amp; Johnson. https://www.jnj.com/stelara-ustekinumab-approved-by-the-u-s-food-and-drug-administration-to-treat-pediatric-patients-with-active-psoriatic-arthritis (Accessed on October 22, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nash P. Therapies for axial disease in psoriatic arthritis. A systematic review. J Rheumatol 2006; 33:1431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gladman DD, Blake R, Brubacher B, Farewell VT. Chloroquine therapy in psoriatic arthritis. J Rheumatol 1992; 19:1724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken) 2019; 71:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol 2019; 71:1599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss PF, Fuhlbrigge RC, von Scheven E, et al. Children With Enthesitis-Related Arthritis and Possible Benefits From Treatments for Adults With Spondyloarthritis. Arthritis Care Res (Hoboken) 2022; 74:1058.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jadon DR, Sengupta R, Nightingale A, et al. Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum Dis 2017; 76:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss PF, Xiao R, Biko DM, et al. Detection of inflammatory sacroiliitis in children with magnetic resonance imaging: is gadolinium contrast enhancement necessary? Arthritis Rheumatol 2015; 67:2250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wanders A, Heijde Dv, Landewé R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; 52:1756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sieper J, Listing J, Poddubnyy D, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis 2016; 75:1438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liew JW, Ward MM, Reveille JD, et al. Nonsteroidal Antiinflammatory Drug Use and Association With Incident Hypertension in Ankylosing Spondylitis. Arthritis Care Res (Hoboken) 2020; 72:1645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgos-Vargas R, Tse SM, Horneff G, et al. A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis. Arthritis Care Res (Hoboken) 2015; 67:1503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum 2008; 58:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Heijde D, Landewé R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008; 58:3063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008; 58:1981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013; 65:2645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karmacharya P, Duarte-Garcia A, Dubreuil M, et al. Effect of Therapy on Radiographic Progression in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis. Arthritis Rheumatol 2020; 72:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jadon DR, Shaddick G, Jobling A, et al. Clinical outcomes and progression to orthopedic surgery in juvenile- versus adult-onset ankylosing spondylitis. Arthritis Care Res (Hoboken) 2015; 67:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baeten D, Sieper J, Braun J, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med 2015; 373:2534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis 2017; 76:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther 2017; 19:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet 2018; 392:2441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet 2020; 395:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet 2019; 394:2108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deodhar A, Gensler LS, Sieper J, et al. Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. Arthritis Rheumatol 2019; 71:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris A, Rogers M, Fischer G, Williams K. Childhood psoriasis: a clinical review of 1262 cases. Pediatr Dermatol 2001; 18:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoll ML, Zurakowski D, Nigrovic LE, et al. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum 2006; 54:3564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Care Res (Hoboken) 2019; 71:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ekelund M, Aalto K, Fasth A, et al. Psoriasis and associated variables in classification and outcome of juvenile idiopathic arthritis - an eight-year follow-up study. Pediatr Rheumatol Online J 2017; 15:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberton DM, Cabral DA, Malleson PN, Petty RE. Juvenile psoriatic arthritis: followup and evaluation of diagnostic criteria. J Rheumatol 1996; 23:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flatø B, Lien G, Smerdel-Ramoya A, Vinje O. Juvenile psoriatic arthritis: longterm outcome and differentiation from other subtypes of juvenile idiopathic arthritis. J Rheumatol 2009; 36:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guzman J, Oen K, Tucker LB, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 2015; 74:1854.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16366 Version 19.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31021537" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7462277" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Leg-length discrepancies in monoarticular and pauciarticular juvenile rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13395263" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Growth in Still's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12165590" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Identifying children with chronic arthritis based on chief complaints: absence of predictive value for musculoskeletal pain as an indicator of rheumatic disease in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16583404" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Care of the adult with juvenile rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22859354" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18975367" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Optimal treatment of knee monarthritis in juvenile idiopathic arthritis: a decision analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25774101" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Enthesitis as a component of dactylitis in psoriatic juvenile idiopathic arthritis: histology of an established clinical entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27403334" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32418040" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Effectiveness of steroid injection for hand psoriatic dactylitis: results from a multicentre prospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26669913" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23942868" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27098404" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29550766" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29635379" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29045212" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16724372" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Therapies for peripheral joint disease in psoriatic arthritis. A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9588731" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11327261" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Sulfasalazine for the management of juvenile rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8587078" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8670601" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32386593" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33334727" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35961761" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27998952" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28148698" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The Juvenile Psoriatic Arthritis Cohort in the CARRA Registry: Clinical Characteristics, Classification, and Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33731872" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Biological classification of childhood arthritis: roadmap to a molecular nomenclature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18632147" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21128258" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28473423" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23769296" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31565242" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31565242" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16724371" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Therapies for axial disease in psoriatic arthritis. A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1491390" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Chloroquine therapy in psoriatic arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31021516" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31436036" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33278336" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Children With Enthesitis-Related Arthritis and Possible Benefits From Treatments for Adults With Spondyloarthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27913376" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25892309" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Detection of inflammatory sacroiliitis in children with magnetic resonance imaging: is gadolinium contrast enhancement necessary?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15934081" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26242443" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31529687" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Nonsteroidal Antiinflammatory Drug Use and Association With Incident Hypertension in Ankylosing Spondylitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26223543" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18311819" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18821688" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18576337" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23818109" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The impact of tumor necrosis factorαinhibitors on radiographic progression in ankylosing spondylitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31960614" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Effect of Therapy on Radiographic Progression in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25331747" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Clinical outcomes and progression to orthopedic surgery in juvenile- versus adult-onset ankylosing spondylitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26699169" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27582421" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29273067" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30360964" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31813637" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31732180" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30225992" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11437997" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Childhood psoriasis: a clinical review of 1262 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17075862" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Patients with juvenile psoriatic arthritis comprise two distinct populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31021540" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28222745" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Psoriasis and associated variables in classification and outcome of juvenile idiopathic arthritis - an eight-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8838527" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Juvenile psoriatic arthritis: followup and evaluation of diagnostic criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19208605" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Juvenile psoriatic arthritis: longterm outcome and differentiation from other subtypes of juvenile idiopathic arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24842571" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
